Metsera (MTSR) Competitors $24.11 +0.81 (+3.48%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. RVMD, LNTH, BBIO, TGTX, TLX, LEGN, SRPT, BPMC, NUVL, and VRNAShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Nuvalent (NUVL), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Legend Biotech Sarepta Therapeutics Blueprint Medicines Nuvalent Verona Pharma Revolution Medicines (NASDAQ:RVMD) and Metsera (NASDAQ:MTSR) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Does the media favor RVMD or MTSR? In the previous week, Revolution Medicines had 18 more articles in the media than Metsera. MarketBeat recorded 23 mentions for Revolution Medicines and 5 mentions for Metsera. Revolution Medicines' average media sentiment score of 1.28 beat Metsera's score of 0.72 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 16 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metsera 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in RVMD or MTSR? Revolution Medicines received 94 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 77.17% of users gave Revolution Medicines an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes9877.17% Underperform Votes2922.83% MetseraOutperform Votes4100.00% Underperform VotesNo Votes Which has higher valuation and earnings, RVMD or MTSR? Metsera has lower revenue, but higher earnings than Revolution Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$742K10,117.48-$436.37M-$3.57-11.31MetseraN/AN/AN/AN/AN/A Do institutionals & insiders have more ownership in RVMD or MTSR? 94.3% of Revolution Medicines shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is RVMD or MTSR more profitable? Metsera's return on equity of 0.00% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% Metsera N/A N/A N/A Do analysts prefer RVMD or MTSR? Revolution Medicines currently has a consensus price target of $66.67, suggesting a potential upside of 65.10%. Metsera has a consensus price target of $47.00, suggesting a potential upside of 94.94%. Given Metsera's higher possible upside, analysts plainly believe Metsera is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRevolution Medicines beats Metsera on 7 of the 11 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.53B$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5718.48Price / SalesN/A242.70395.64103.60Price / CashN/A65.8538.1834.62Price / BookN/A6.516.774.25Net IncomeN/A$143.21M$3.22B$248.23M7 Day Performance13.83%1.97%1.46%0.89%1 Month Performance-1.63%6.89%3.98%3.53%1 Year PerformanceN/A-2.52%16.14%5.09% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$24.11+3.5%$47.00+94.9%N/A$2.53BN/A0.0081News CoverageRVMDRevolution Medicines3.7636 of 5 stars$38.77+0.5%$66.67+72.0%+8.3%$7.21B$742,000.00-10.80250Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9711 of 5 stars$101.77-1.8%$129.43+27.2%+56.8%$6.97B$1.53B16.93700Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$36.31+1.0%$53.00+46.0%+49.7%$6.89B$221.90M-12.74400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap UpTGTXTG Therapeutics3.327 of 5 stars$41.33+2.6%$40.67-1.6%+233.2%$6.56B$329.00M-413.26290Upcoming EarningsNews CoveragePositive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.80-2.2%$22.00+17.0%N/A$6.49B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownLEGNLegend Biotech2.6303 of 5 stars$34.28+0.1%$78.82+129.9%-20.1%$6.30B$627.24M-36.081,070Positive NewsSRPTSarepta Therapeutics4.7345 of 5 stars$60.44-2.1%$158.70+162.6%-50.7%$5.86B$1.90B48.35840BPMCBlueprint Medicines2.5598 of 5 stars$87.66+1.8%$124.68+42.2%-2.0%$5.60B$508.82M-81.17640Earnings ReportAnalyst ForecastNews CoveragePositive NewsNUVLNuvalent1.891 of 5 stars$73.48-0.7%$115.50+57.2%+11.4%$5.30BN/A-21.1840Upcoming EarningsPositive NewsVRNAVerona Pharma2.8962 of 5 stars$65.46+1.0%$75.43+15.2%+366.5%$5.29B$42.28M-34.0930Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies RVMD Alternatives LNTH Alternatives BBIO Alternatives TGTX Alternatives TLX Alternatives LEGN Alternatives SRPT Alternatives BPMC Alternatives NUVL Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTSR Stock Free MTSR Stock Alerts